In adults with atherosclerosis or diabetes and LDL cholesterol ≥90 mg/dL but no prior heart attack or stroke, monthly subcutaneous evolocumab (140 mg every two weeks) for a median of 4.6 years reduces the risk of first major cardiovascular events including revascularization by 19% compared to placebo, with a hazard ratio of 0.81 for the 4-point MACE endpoint.

Source: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports

74score

Challenges

0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect

1 study reviewed

In plain English

In adults with atherosclerosis or diabetes and high LDL cholesterol but no prior heart attack or stroke, monthly injections of evolocumab for about 4.6 years lower the rate of first major cardiovascular events, including procedures to restore blood flow, by 19% compared to no treatment.

See the scientific wording

In adults with atherosclerosis or diabetes and LDL cholesterol ≥90 mg/dL but no prior heart attack or stroke, monthly subcutaneous evolocumab (140 mg every two weeks) for a median of 4.6 years reduces the risk of first major cardiovascular events including revascularization by 19% compared to placebo, with a hazard ratio of 0.81 for the 4-point MACE endpoint.

Why this might work

A drug blocks a protein that normally destroys receptors on the liver that remove bad cholesterol from the blood. With more receptors available, the liver pulls more bad cholesterol out of the bloodstream. Lower cholesterol levels slow the growth of fatty buildup in arteries and make existing plaques more stable, reducing the chance of blockages that cause heart attacks, strokes, or the need for artery-opening procedures.

Verified mechanismbased on 1 study

What the research says

1 study

Study: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
For people with high cholesterol due to artery disease or diabetes but no prior heart attack or stroke, getting evolocumab shots every two weeks for almost five years lowered their chance of having a first heart attack, stroke, or needing a procedure to open blocked arteries by about 19% compared to those who didn’t get the drug.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.